<DOC>
	<DOCNO>NCT00987233</DOCNO>
	<brief_summary>A randomized , double-blind , placebo-controlled parallel-group study , compare bioequivalence triamcinolone acetonide aqueous nasal spray ( Apotex , Inc. ) Nasacort® AQ nasal spray ( Sanofi-Aventis Pharmaceutical Products , Inc. ) treatment seasonal allergic rhinitis .</brief_summary>
	<brief_title>A Study Comparing Bioequivalence Triamcinolone Acetonide Aqueous Nasal Spray ( Apotex , Inc. ) That Nasacort® AQ Nasal Spray ( Sanofi-Aventis Pharmaceutical Products , Inc. ) In Treatment Seasonal Allergic Rhinitis</brief_title>
	<detailed_description />
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Rhinitis , Allergic , Seasonal</mesh_term>
	<mesh_term>Triamcinolone hexacetonide</mesh_term>
	<mesh_term>Triamcinolone Acetonide</mesh_term>
	<mesh_term>Triamcinolone</mesh_term>
	<mesh_term>Triamcinolone diacetate</mesh_term>
	<criteria>Understands requirement study provide write informed consent ; Is male female 18 65 year age ; At least 2year history seasonal allergic rhinitis ; The presence IgEmediated hypersensitivity local pollen confirm positive response either skin prick intradermal test within past 12 month . A positive response define wheal diameter least 3 mm large control skin prick test least 7 mm large control intradermal test ; In order enter placebo leadin period , subject must score least 6 24hour reflective TNSS complete Visit 2 ; Is general good health determine screen evaluation judgment Investigator ; If female childbearing potential , pregnant ( confirm negative urine pregnancy test ) , nonlactating , use reliable birth control measure throughout study . Female child bear potential define female experienced menarche , undergone successful surgical sterilization : hysterectomy , bilateral oophorectomy ovariectomy , bilateral tubal ligation salpingectomy ; postmenopausal least 1 year . ; If receive immunotherapy , must stable maintenance regimen least 30 day Visit 1 , maintain dose throughout study ( Low dose antibiotic therapy give prophylactically started prior Day 7 acceptable . ) ; Has use systemic steroid topical steroid ( inhale , intranasal , intraocular ) within 30 day Visit 2 ; Is capable tolerate intranasal application study drug ; Is willing able comply requirement protocol intend complete study . Evidence unstable clinically significant , hematopoietic , malignant , cardiovascular , hepatic , renal , neurologic , psychiatric , autoimmune disorder/condition/disease opinion Investigator could place subject increase risk complication , interfere study participation , confound study objective ; Presence history ocular herpes simplex , cataract , glaucoma ; Inability avoid exposure chickenpox measles ; Respiratory tract infection within two week prior screen ; Infection require oral antibiotic treatment two week prior screen ; Significant pulmonary disease and/or active asthma require daily medication ; Signs symptom nasal polyp , deviate septum , condition , opinion Investigator , may result erroneous study data ; Known intolerance ( hypersensitivity serious adverse reaction ) corticosteroid ; History within last 5 year current evidence alcohol drug abuse ; Current use therapy medication ( e.g. , tricyclic antidepressant others . See Section 8.1 , Prohibited Medications ) would affect assessment effectiveness study drug ; Unable withhold prohibit medication ( see Section 8.1 , Prohibited Medications ) ; Use follow prior start singleblind placebo leadin visit ( Visit 2 ) within time period specify : Time prior Visit 2 Intranasal systemic corticosteroid 30 day Ocular corticosteroid 30 day Intranasal cromolyn 14 day Leukotriene inhibitor 14 day Loratadine10 day Intranasal systemic antihistamine ( include sleep diet aid cold preparation ) 3 day Has receive investigational drug participate investigational research study within 30 day enter study ; Documented evidence acute significant chronic sinusitis , determine investigator ; Rhinitis medicamentosa ; Planned travel outside study area substantial portion study period .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2009</verification_date>
</DOC>